What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform health care and sustainability?

FL94 Inc., is a privately held, early-stage biotechnology company pioneering Protein Editing. At FL94 we create small molecules that edit protein structure and function to unlock presently undruggable targets and a broad array of novel chemistry modalities. Our platform integrates novel small molecule chemistry and chemoproteomic discovery technologies with machine learning to enable generative design of protein editing chemistries. FL94 is backed by Flagship Pioneering, bringing the courage, vision, and resources to guide FL94 from platform validation to patient impact.We are seeking collaborative, relentless problem solvers that share our passion for impact to join us! 

Position Summary:

FL94 is seeking an ambitious, creative, and talented Scientist, Discovery Biologyto join our research team. You will be part of the team responsible for leveraging our novel platform to develop first-in-class medicines and new chemical modalities. The ideal candidate brings expertise in building high quality and high throughput cell based & biochemical based assays with a passion for discovery and development of small molecule drugs. A background in industrial drug discovery and experience with novel heterobifunctional modalities, like PROTACs, is preferred. 

Successful candidates will be able to thrive in a fast-paced, action-oriented, team environment and display a clear passion for science and impact. The individual will have demonstrated evidence of technical expertise and experience overcoming challenges and moving projects forward with urgency.  Experience guiding junior scientists technically and strategically will be important.  They will be interested in contributing at the bench and be dedicated to scientific development of themselves and their team.

Key Responsibilities:

• Responsible for the design, planning, and execution of preclinical small molecule discovery programs across a range of therapeutic areas
• Develop high-throughput in vitro screens to assess targets, biochemically evaluate small molecules identified through FL94’s chemoproteomics platform, and broadly support drug discovery of several high value unprecedented targets
• Build a robust infrastructure of laboratory protocols, tools, and systems that will scale efficiently
• Manage outsourced biochemistry, cell biology, and in vivo biology resources, establishing and maintaining excellent working relationships with CROs and academic collaborators
• Work collaboratively in cross-functional teams with chemistry, proteomics, drug discovery and AI/machine learning
• Ensure rapid and accurate turnaround of data, to agreed timelines, to drive achievement of key project goals
• Translate experimental data into meaningful insights, and present the analyzed data in team meetings

Qualifications:

• Ph.D. or equivalent in molecular biology, cellular biology, biochemistry, pharmacology, or related fields
• Sound knowledge of disciplines involved in drug discovery (cell-based disease models, biochemical and biophysical methods, HT screening, LC-MS)
• Therapeutic domain expertise in oncology, immunology, genetic disorders, or neurobiology
• Experience working with induced proximity technologies, such as PROTACs and molecular glues, is a plus.
• Passion for and experience working with therapeutic companies committed to integration of AI / Data Science across all layers of the business is a plus
• Demonstrated ability to work within highly skilled teams in a fast-paced, quickly evolving technical environment
• Excellent communication and presentation skills, capable of conveying scientific information in a concise and effective manner.

Location: Cambridge, MA

More About Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $100 billion in aggregate value. To date, Flagship has deployed over $3.1 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises  transformative companies, including  Moderna (NASDAQ: MRNA), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Generate Biomedicines, Tessera Tx, and others.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. 

Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.